Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
GABAA positive allosteric modulator (15) ·
None (3) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
NMDA antagonist (3) ·
GABAA potentiator and direct activator (2) ·
Irreversible selective MAO-B inhibitor (2) ·
Melatonin receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist (2)
uses:
None (64) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
None (64) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 66 results in range #1 to #66.